Angelini Pharma financial data

Angelini Pharma financial data

In 2023, Angelini Pharma consolidated revenues of 1,220.9 million euros (+3.5% vs 2022), of which 49% generated on markets outside of Italy, with an EBITDA of 243.8 million euros (+12.2% vs 2022) and an EBITDA margin of 20% (18.4% in 2022). This growth reflects the commitment to innovation and quality of care. During the year, the launch of the innovative anti-epilepsy molecule, cenobamate, was completed in the main European Countries. Today, the company offers therapeutic solutions for three of the biggest central nervous system (CNS) disorders – epilepsy, schizophrenia and depression. In 2023, Angelini Pharma also signed an exclusive agreement with JCR Pharmaceuticals to develop new organic therapies for the treatment of epilepsy. This agreement makes it possible to explore new therapeutic frontiers, confirming the ambitious investment strategy of Angelini Industries in the pharmaceutical sector. Driven by strong ethics, responsibility and innovation, Angelini Pharma strives to improve the quality of life of patients through investments, research and continuous activities to raise awareness of diseases.

Angelini Pharma - Financial Data 2023

  1. 1,220.9 MLN€ Revenues
  2. 243.8 MLN€ EBITDA
  3. 20% EBITDA MARGIN
  4. 135.6 MLN€ OPERATING CASH FLOW
  5. 55.9 MLN€ R&D INVESTMENTS

Revenues by Business Area

1.220,9 mln € revenues

  • 14.5% (+27.2% vs PY) Central Nervous System
  • 40.9% Specialty & Primary Care
  • 34.5% Consumer Healthcare
  • 10.1% Other (raw materials & consumer goods)

BUSINESS AREAS and R&D

Ethics, Performance and Innovation

Angelini Pharma is committed to the research, development and marketing of therapeutic solutions, with a particular focus on: Central Nervous System (CNS), Specialty and Primary Care, Consumer Healthcare.

Central Nervous System

The CNS is an area of strategic development for Angelini Pharma, thanks to a potential market estimated at approximately 150-170 billion euros, and an average growth of 6-8% per year over the next 5 years (source: IQVIA). The CNS area of Angelini Pharma grew by 27.2% in 2023, accounting for 14.5% of the revenues, and could continue to grow more than the market in the next 5 years.

Specialty & Primary Care e Consumer Healthcare

The two business units Specialty & Primary Care and Consumer Healthcare contributed 40.9% and 34.5% to the total revenues respectively, and in 2023 recorded an overall increase of 3.0%, by leveraging established global and local brands with great success, particularly in the area of pain therapy and flu symptoms. The remaining 10.1% of the revenues were generated by Raw Materials and Consumer Goods products, typically in large-scale retail channels.

Research & Development

In 2023, Angelini Pharma invested 55.9 million euros in Research and Development, with a particular focus on early research, mental health with various preclinical and clinical activities in support of cenobamate (epilepsy) and trazodone (depression), as well as the development of new personalized therapeutic solutions.